

Faculty Disclosures

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, course directors, planners, moderators, faculty, and all others in control of the educational content of the continuing education activity must disclose all financial relationships with ineligible companies that they may have had within the past 24 months. If an individual refuses to disclose financial relationships, they will be disqualified from being a part of the planning and implementation of the activity. Owners and/or employees of an ineligible company with business lines or products relating to the content of the activity will not be permitted to participate in the planning or execution of any accredited program. All listed relevant financial relationships with ineligible companies for individuals in control of content have been mitigated.

Name	Role in Activity	Ineligible Company	Nature of Relevant Financial Relationship
Bhangoo	Speaker	<ul style="list-style-type: none"> Bristol Myers Squibb, Exelixis, 	<ul style="list-style-type: none"> Speaker
Bollin	Speaker	<ul style="list-style-type: none"> Iovance Biotherapeutics, Nektar Therapeutics 	<ul style="list-style-type: none"> Advisory Role
Daniels	Speaker	<ul style="list-style-type: none"> Bristol Myers Squibb, Iovance Biotherapeutics, Merck & Co. 	<ul style="list-style-type: none"> Research Funding
Dorff	Speaker	<ul style="list-style-type: none"> Astellas, AstraZeneca, Exelixis, Janssen, Pfizer, Seagen 	<ul style="list-style-type: none"> Advisor
Fisher	Speaker	<ul style="list-style-type: none"> Seattle Genetics 	<ul style="list-style-type: none"> Stock
		<ul style="list-style-type: none"> Ipsen, Merck, Novartis 	<ul style="list-style-type: none"> Honorarium
		<ul style="list-style-type: none"> Genentech, Ipsen, Jounce Therapeutics, Merck, Terumo, Taiho Pharmaceutical 	<ul style="list-style-type: none"> Consultant
Goodman	Speaker	<ul style="list-style-type: none"> EUSA Pharma, Seattle Genetics 	<ul style="list-style-type: none"> Consultant
Hecht	Speaker	<ul style="list-style-type: none"> Astellas, AstraZeneca, Concept Pharmaceuticals, Exelixis, Gilead, Sciences, Gritstone, Istari Oncology, Regenacy Pharmaceuticals, Notch Therapeutics 	<ul style="list-style-type: none"> Advisor
		<ul style="list-style-type: none"> Amgen 	<ul style="list-style-type: none"> Speaker
Hermel	Peer Reviewer	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> N/A
Mahindra	Speaker	<ul style="list-style-type: none"> ADC Therapeutics, Bristol Myers Squibb, EUSA Pharma, Epizyme, GlaxoSmithKline, Karyopharm Therapeutics 	<ul style="list-style-type: none"> Advisory
		<ul style="list-style-type: none"> GlaxoSmithKline 	<ul style="list-style-type: none"> Speaker
Mortimer	Speaker	<ul style="list-style-type: none"> AstraZeneca, Novartis, Pfizer 	<ul style="list-style-type: none"> Consultant
		<ul style="list-style-type: none"> AstraZeneca 	<ul style="list-style-type: none"> Research Funding
Natale	Speaker	<ul style="list-style-type: none"> Astex Pharmaceuticals, AstraZeneca, Blueprint Pharmaceuticals, Inspirna Pharmaceuticals, Merck & CO., Molecular Templates 	<ul style="list-style-type: none"> Clinical Research
Savage	Peer Reviewer	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> N/A

Saven	Course Director, Moderator	<ul style="list-style-type: none"> • Celgene, Dova Pharmaceuticals, Inc., Incyte Corporation, Janssen, Pharmacyclics, Seattle Genetics 	<ul style="list-style-type: none"> • Speaker
Srinivas	Speaker	<ul style="list-style-type: none"> • AVEO Pharmaceuticals, Inc., Bayer Pharmaceuticals, Eisai, Janssen Pharmaceuticals, Merck & Co., Novartis, Seagen 	<ul style="list-style-type: none"> • Advisory Board
		<ul style="list-style-type: none"> • Pfizer 	<ul style="list-style-type: none"> • Data Safety Monitoring Committee
CME Committee	CE approval, all final decision-making on activities	<ul style="list-style-type: none"> • None 	<ul style="list-style-type: none"> • N/A
Scripps Conference Services & CME	Plan, manage, implement, and reconcile CE activities	<ul style="list-style-type: none"> • None 	<ul style="list-style-type: none"> • N/A

Glossary of Terms

Ineligible Company

An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. For specific examples of ineligible companies visit www.accme.org/standards.

Financial Relationships

Financial relationships include employee, researcher, consultant, advisor, speaker, independent contractor, research funding, royalties or patent beneficiary, executive role, and ownership interest. Individual stocks and stock options should be disclosed.